Gaddy Anna, Elrggal Mohamed, Madariaga Hector, Kelly Adam, Lerma Edgar, Colbert Gates B
Division of Nephrology, Medical College of Wisconsin, 8700 Watertown Plank Road Milwaukee, WI 53226, USA.
Nephrology Department, Kidney and Urology Center, Alexandria, Egypt.
Dis Mon. 2025 Apr;71(4):101848. doi: 10.1016/j.disamonth.2024.101848. Epub 2025 Jan 2.
Diabetic kidney disease is a leading cause of kidney failure worldwide and is easily detectable with screening examination. Diabetes causes hyperfiltration and activation of the renin-angiotensin aldosterone system by hemodynamic changes within the nephron, which perpetuates damaging physiology. Diagnosis is often clinical after detection of heavy proteinuria in a patient with diabetes,but can be confirmed by observation of histologic stages on kidney biopsy. Mainstays of treatment include angiotensin conversion or receptor blockade, mineralocorticoid receptor blockade, and tight glucose control. Newer agents favored in diabetic kidney disease are sodium glucose-cotransporters and glucagon-like peptide 1 receptor agonists, both for glycemic control and for various methods of reversing damaging physiology.
糖尿病肾病是全球肾衰竭的主要原因,通过筛查检查很容易检测出来。糖尿病通过肾单位内的血流动力学变化导致超滤过以及肾素-血管紧张素-醛固酮系统激活,从而使损害性生理过程持续存在。糖尿病患者出现大量蛋白尿后,诊断通常基于临床症状,但可通过肾活检观察组织学阶段来确诊。治疗的主要方法包括血管紧张素转换或受体阻断、盐皮质激素受体阻断以及严格控制血糖。糖尿病肾病中更受青睐的新型药物是钠葡萄糖协同转运蛋白和胰高血糖素样肽1受体激动剂,二者均可用于控制血糖以及采用多种方法逆转损害性生理过程。